Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
MedImmune LLC |
---|---|
Information provided by: | MedImmune LLC |
ClinicalTrials.gov Identifier: | NCT00860067 |
The objective of this study is to prove that MEDI3250 is at least as effective as two different forms the vaccine, FluMist, by comparing the specific events after dosage.
Condition | Intervention | Phase |
---|---|---|
Healthy |
Biological: MEDI3250 Biological: FluMist/B/Yamagata Biological: FluMist/B/Victoria |
Phase II Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Active Control, Single Group Assignment, Pharmacokinetics/Dynamics Study |
Official Title: | A Randomized, Double-Blind, Active Controlled Study to Evaluate the Immunogenicity of MEDI3250 in Adults 18 to 49 Years of Age |
Estimated Enrollment: | 1800 |
Study Start Date: | March 2009 |
Estimated Study Completion Date: | November 2009 |
Estimated Primary Completion Date: | October 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Active Comparator
MEDI3250
|
Biological: MEDI3250
0.2ml dose at day 0
|
2: Active Comparator
FluMist/B/Yamagata
|
Biological: FluMist/B/Yamagata
0.2ml dose at day 0
|
3: Active Comparator
FluMist/B/Victoria
|
Biological: FluMist/B/Victoria
0.2ml dose at day 0
|
The primary objective of this study is to demonstrate the immunologic noninferiority of MEDI3250 to 2 formulations of FluMist by comparing the strain-specific GMTs post dosing.
Ages Eligible for Study: | 18 Years to 49 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Current or expected receipt of immunosuppressive medications (inhaled and topical corticosteroids are permitted) including corticosteroids (≥ 20 mg/day of prednisone equivalent given daily or on alternate days for
United States, California | |
California Research Foundation | |
San Diego, California, United States, 92103-6204 | |
Benchmark Research - San Francisco Site | |
San Francisco, California, United States, 94102 | |
Benchmark Research - Sacramento Site | |
Sacramento, California, United States, 95816 | |
United States, Florida | |
Pharmax Research Clinic, Inc | |
Miami, Florida, United States, 33126 | |
University Clinical Research, Inc | |
Pembroke Pines, Florida, United States, 33024 | |
University Clinical Research Deland, Inc | |
Deland, Florida, United States, 32720 | |
Internal Medicine and Rheumatology | |
South Miami, Florida, United States, 33143 | |
United States, Georgia | |
Clinical Research Atlanta | |
Stockbridge, Georgia, United States, 32801 | |
United States, Kansas | |
Vince and Associates Clinical Research | |
Overland Park, Kansas, United States, 66212 | |
United States, Kentucky | |
Kentucky Pediatric / Adult Research | |
Bardstown, Kentucky, United States, 40004 | |
United States, Missouri | |
The Center for Pharmaceutical Research | |
Kansas City, Missouri, United States, 64114 | |
Sundance Clinical Research, LLC | |
St. Louis, Missouri, United States, 63141 | |
United States, Nebraska | |
Meridian Clinical Research | |
Omaha, Nebraska, United States, 68314 | |
United States, New York | |
Rochester Clinical Research, Inc. | |
Rochester, New York, United States, 14609 | |
United States, Tennessee | |
Clinical Research Associates, Inc | |
Nashville, Tennessee, United States, 37201 | |
United States, Texas | |
Benchmark Research - Austin Site | |
Austin, Texas, United States, 78705 | |
Benchmark Research - Ft. Worth Site | |
Ft. Worth, Texas, United States, 76135 | |
United States, Utah | |
Advanced Clinical Research | |
West Jordan, Utah, United States, 84088 |
Study Director: | Judith Falloon, M.D. | MedImmune LLC |
Responsible Party: | MedImmune LLC ( Judith Falloon, M.D. ) |
Study ID Numbers: | MI-CP185 |
Study First Received: | March 9, 2009 |
Last Updated: | April 7, 2009 |
ClinicalTrials.gov Identifier: | NCT00860067 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Healthy |